Business Segments · Research and development expense
Cardiovascular — Research and development expense
Medtronic Cardiovascular — Research and development expense decreased by 5.0% to $284.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.5%, from $248.00M to $284.00M.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2023
Last reportedQ1 2026
How to read this metric
An increase suggests a focus on future product innovation, while a decrease may indicate cost-cutting or a shift in strategic R&D priorities.
Detailed definition
This represents the costs incurred by the cardiovascular business segment to research, design, and develop new medical d...
Peer comparison
Comparable to R&D spending in specialized medical technology segments at peers like Abbott or Boston Scientific.
Metric ID:
mdt_segment_cardiovascular_research_and_development_expenseHistorical Data
11 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $203.75M | $203.75M | $203.75M | $203.75M | $257.00M | $256.00M | $248.00M | $331.00M | $280.00M | $299.00M | $284.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +26.1% | -0.4% | -3.1% | +33.5% | -15.4% | +6.8% | -5.0% |
| YoY Change | — | — | — | — | +26.1% | +25.6% | — | — | +8.9% | +16.8% | +14.5% |
Range$203.75M – $331.00M
CAGR+14.2%
Avg YoY Growth+18.4%
Median YoY Growth+16.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's cardiovascular — research and development expense?
- Medtronic (MDT) reported cardiovascular — research and development expense of $284.00M in Q1 2026.
- How has Medtronic's cardiovascular — research and development expense changed year-over-year?
- Medtronic's cardiovascular — research and development expense increased by 14.5% year-over-year, from $248.00M to $284.00M.
- What does cardiovascular — research and development expense mean?
- The total spending on research and development activities specifically for the cardiovascular product segment.